Metropolis Healthcare Reports 13.2% Profit Growth in Q2 FY26, Declares Interim Dividend

Metropolis Healthcare Ltd reported a robust financial performance for the second quarter of fiscal year 2026 (Q2 FY26), ending September 2025. The diagnostic chain's net profit saw a significant 13.2% year-on-year jump, reaching ₹53 crore compared to ₹47 crore in the same period last year. Total revenue for the quarter experienced a substantial increase of 22.7%, growing to ₹429 crore from ₹349.8 crore in Q2 FY25.

Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) also showed strong growth, rising by 20.5% year-on-year to ₹108.6 crore. The EBITDA margin was reported at 25.3%, a slight decrease from 25.7% in the previous year's comparable quarter. The company attributed this growth to an 11% increase in patient volumes and a 12% rise in test volumes. Both Business-to-Consumer (B2C) and Business-to-Business (B2B) segments demonstrated healthy demand, with revenues growing 16% and 33% year-on-year, respectively.

Revenue per patient (RPP) and revenue per test (RPT) increased by 11% and 10% year-on-year, driven by brand trust and premium offerings. High-value services like the TruHealth wellness and Specialty portfolios saw significant growth of approximately 24% and 33% year-on-year. Geographically, North India's revenue contribution increased to 19%, and Tier III cities showed 13% revenue growth, indicating expanding market reach. Acquired entities, including Core Diagnostics, also showed positive contributions.

Ameera Shah, Promoter and Executive Chairperson, highlighted the successful integration strategy and the company's focus on genomics, AI-enabled innovation, and digital transformation to drive value and expand access to quality diagnostics.

In addition to its financial results, Metropolis Healthcare announced an interim dividend of ₹4 per equity share for FY26. The record date for this dividend is November 11, 2025.

Impact: This news is likely to positively impact Metropolis Healthcare's stock performance due to strong earnings growth, robust revenue expansion, and effective strategic execution. The dividend announcement also adds shareholder value. The overall diagnostics sector may also see a positive sentiment. Rating: 7/10

Difficult Terms: PAT: Stands for Profit After Tax, which is the profit remaining after all expenses and taxes have been deducted. EBITDA: Stands for Earnings Before Interest, Tax, Depreciation, and Amortisation. It is a measure of a company's operating performance. EBITDA Margin: Calculated as EBITDA divided by total revenue, expressed as a percentage. It indicates profitability from core operations. B2C: Stands for Business-to-Consumer, referring to sales made directly to individual customers. B2B: Stands for Business-to-Business, referring to sales made to other businesses. RPP: Stands for Revenue Per Patient, the average revenue generated from each patient. RPT: Stands for Revenue Per Test, the average revenue generated from each diagnostic test. Genomics: The study of an organism's complete set of DNA. AI: Stands for Artificial Intelligence, the simulation of human intelligence processes by machines. Digital Transformation: The integration of digital technology into all areas of a business, fundamentally changing how it operates and delivers value to customers.